Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Immunology
Импакт фактор: 1.352 5-летний Импакт фактор: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Печать: 1040-8401
ISSN Онлайн: 2162-6472

Том 39, 2019 Том 38, 2018 Том 37, 2017 Том 36, 2016 Том 35, 2015 Том 34, 2014 Том 33, 2013 Том 32, 2012 Том 31, 2011 Том 30, 2010 Том 29, 2009 Том 28, 2008 Том 27, 2007 Том 26, 2006 Том 25, 2005 Том 24, 2004 Том 23, 2003 Том 22, 2002 Том 21, 2001 Том 20, 2000 Том 19, 1999 Том 18, 1998 Том 17, 1997 Том 16, 1996 Том 15, 1995 Том 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v23.i4.40
16 pages

Is an Improved Measles-Mumps-Rubella Vaccine Necessary or Feasible?

Gregory J. Atkins
Virus Group, Moyne Institute, Trinity College, Dublin 2, Ireland
S. Louise Cosby
Department of Microbiology, Whitla Medical Building, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland, UK

Краткое описание

The measles-mumps-rubella (MMR) vaccine has been very effective in the elimination of disease and has high biosafety. However, it has been associated with several adverse effects and has recently caused controversy with regard to its possible association with inflammatory bowel disease and autism. This has been postulated to be a property of the measles component of the vaccine, and a "new variant" autism has recently been described and suggested to be associated with vaccine virus. Although one study has reported the presence of measles RNA in inflammatory bowel disease associated with autism, this has not been independently confirmed. This and most of the other demonstrated or perceived adverse effects of the MMR vaccine could theoretically be ascribed to its composition as a mixture of three live replicating viruses, one of which (measles) can induce immunosuppression, although this hypothesis is speculative. It may nonetheless be desirable to improve the biosafety of the MMR vaccine by the development of a nonreplicating vaccine that will stimulate efficient immunity and protection. DNA vaccines for measles, mumps, and rubella viruses have been constructed and tested in animal models but are poorly immunogenic. Several other prototype candidate vaccines are possible, including those based on the rubella virus component of the vaccine as a vector.

Articles with similar content:

DNA Vaccines – A Modern Gimmick or a Boon to Vaccinology?
Critical Reviews™ in Immunology, Vol.37, 2017, issue 2-6
Kevin L. Karem, Barry T. Rouse, Elanchezhiyan Manickan
DNA Vaccines − A Modern Gimmick or a Boon to Vaccinology?
Critical Reviews™ in Immunology, Vol.17, 1997, issue 2
Kevin L. Karem, Barry T. Rouse, Elanchezhiyan Manickan
Victory and Defeat in the Induction of a Therapeutic Response through Vaccine Therapy for Human and Canine Brain Tumors: A Review of the State of the Art
Critical Reviews™ in Immunology, Vol.34, 2014, issue 5
Nate N. Waldron , G Elizabeth Pluhar, Rob Shaver, Brian M. Andersen, Michael R. Olin, Christopher L. Moertel
Options and Opportunities for Clinical Management and Treatment of Psoriasis
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.30, 2013, issue 1
Udita Agrawal, Devyani Dube, Madhu Gupta, Suresh P. Vyas
CD40 Signaling to the Rescue: A CD8 Exhaustion Perspective in Chronic Infectious Diseases
Critical Reviews™ in Immunology, Vol.33, 2013, issue 4
Dustin A. Cobb, Imtiaz A. Khan, Rajarshi Bhadra